Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development of beta 2-selective, long-acting agonists]

N Inagaki1, H Nagai

  • 1Department of Pharmacology, Gifu Pharmaceutical University.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis.

The Journal of infectious diseases·1995
Same author

Genomic aberrations in human hepatoblastomas detected by 2-dimensional gel analysis.

Cancer research·1995
Same author

Effect of some immunosuppressors on allergic bronchial inflammation and airway hyperresponsiveness in mice.

International archives of allergy and immunology·1995
Same author

Nizatidine accelerates gastric emptying of a solid meal in rats.

Digestive diseases and sciences·1995
Same author

[Detection and quantitation of cytomegalovirus DNA in plasma from patients with cytomegalovirus pneumonia].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases·1995
Same author

[The efficacy of granisetron as a prophylactic anti-emetic agent used in conjunction with MCNU and VP16 chemotherapeutic regimens in the management of a pediatric case of hypothalamic anaplastic astrocytoma].

Gan to kagaku ryoho. Cancer & chemotherapy·1995

Regular use of beta 2-agonists for asthma can lead to tolerance and increased risks. Newer, highly selective beta 2-agonists offer improved safety and effectiveness, particularly for late asthmatic responses.

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Context:

  • Beta 2-agonists are primary bronchodilators for symptomatic asthma treatment.
  • Regular use of beta 2-agonists can induce tolerance and worsen asthma control.
  • Over-treatment is linked to increased risk of severe asthma exacerbations.

Purpose:

  • To explore the development and efficacy of novel beta 2-selective agonists.
  • To address cardiovascular side effects associated with older beta 2-agonists.
  • To evaluate the effectiveness of new agents in managing late asthmatic responses.

Summary:

  • Newly developed beta 2-selective agonists are structurally stable and long-acting.
  • These advanced compounds aim to reduce cardiovascular side effects.
  • They show potential efficacy in treating late asthmatic responses, unlike conventional beta-agonists.

Related Experiment Videos

Impact:

  • Potential for improved asthma management with enhanced safety profiles.
  • Offers new therapeutic options for patients experiencing tolerance to existing treatments.
  • May reduce the incidence of severe asthma attacks and associated mortality.